FDA approves hemophilia A drug for children January 09, 2017 By Christine Blank FDA recently expanded the use of antihemophilic factor (recombinant), pegylated (Adynovate, Shire plc) for hemophilia A patients under 12 years old. Why 2016 drug approvals fell January 02, 2017 By Christine Blank While FDA approved far fewer new drugs in 2016 than 2015, the agency quickly approved novel and breakthrough therapies. New device could be breakthrough for diabetics January 02, 2017 By Christine Blank FDA recently expanded approval of the G5 Mobile Continuous Glucose Monitoring System (Dexcom) to allow for replacement of fingerstick blood glucose (sugar) testing for diabetics. Advanced ovarian cancer drug approved December 26, 2016 By Christine Blank FDA recently approved rucaparib (Rubraca, Clovis Oncology) tablets to treat patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer, who have been treated with 2 or more chemotherapies. FDA green lights first treatment for rare spinal disease December 26, 2016 By Christine Blank FDA approved nusinersen (Spinraza, Biogen), the first drug to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. New diabetes combo drug available soon December 19, 2016 By Christine Blank A new combination drug for type 2 diabetes will available in the US in the coming months. FDA issues warnings over anesthesia, diabetes drugs December 16, 2016 By Christine Blank FDA issued two important drug warnings this week: one linking certain diabetes medications to bladder cancer and another about the use of general anesthetic and sedation drugs during pregnancy. FDA approves expansion of Avastin in ovarian cancer December 08, 2016 By Christine Blank FDA recently approved bevacizumab (Avastin, Genentech) for patients with platinum-sensitive recurrent epithelial ovarian (psOC), fallopian tube or primary peritoneal cancer. New drug indication could net more than $1 billion December 05, 2016 By Christine Blank FDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion. FDA approves 2 injectable diabetes drugs November 28, 2016 By Christine Blank Two new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA.